Janux Therapeutics (JANX) Equity Ratio: 2020-2025
Historic Equity Ratio for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to 0.95.
- Janux Therapeutics' Equity Ratio rose 0.95% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year increase of 0.95%. This contributed to the annual value of 0.96 for FY2024, which is 6.44% up from last year.
- Per Janux Therapeutics' latest filing, its Equity Ratio stood at 0.95 for Q3 2025, which was down 0.69% from 0.96 recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Equity Ratio registered a high of 0.97 during Q2 2021, and its lowest value of 0.88 during Q2 2023.
- In the last 3 years, Janux Therapeutics' Equity Ratio had a median value of 0.95 in 2024 and averaged 0.93.
- Its Equity Ratio has fluctuated over the past 5 years, first surged by 206.85% in 2021, then decreased by 8.71% in 2023.
- Janux Therapeutics' Equity Ratio (Quarterly) stood at 0.96 in 2021, then decreased by 8.64% to 0.88 in 2022, then climbed by 2.73% to 0.91 in 2023, then rose by 6.44% to 0.96 in 2024, then climbed by 0.95% to 0.95 in 2025.
- Its last three reported values are 0.95 in Q3 2025, 0.96 for Q2 2025, and 0.96 during Q1 2025.